ERBB2 and adenocarcinoma: HER2 amplification seemed to have a controversial role on the prognosis of NSCLC, while HER2 overexpression was a marker of poor prognosis, especially for adenocarcinoma, early-stage NSCLC and small cell lung cancer (SCLC) as suggested by a meta-analysis (36).